The neoadjuvant therapy of hepatocellular carcinoma:current status and prospects
10.7659/j.issn.1005-6947.250404
- VernacularTitle:肝细胞癌的新辅助治疗:现状与展望
- Author:
Lei ZHAO
1
Author Information
1. 山东第一医科大学附属肿瘤医院(山东省肿瘤医院)肝胆外科,山东 济南 250117;新疆医科大学附属肿瘤医院,新疆 乌鲁木齐 830000
- Publication Type:Journal Article
- Keywords:
Carcinoma,Hepatocellular;
Neoadjuvant Therapy;
Immune Checkpoint Inhibitors
- From:
Chinese Journal of General Surgery
2025;34(7):1347-1352
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)remains highly prevalent in China and worldwide,with less than 20%of newly diagnosed patients eligible for radical resection and a postoperative 5-year recurrence rate as high as 70%.Perioperative therapy is a key strategy to reduce recurrence,yet evidence for neoadjuvant therapy in HCC is still limited.In recent years,immune checkpoint inhibitors(ICIs)have shown significant progress in HCC treatment,and their potential in the neoadjuvant setting has attracted growing attention.Neoadjuvant immunotherapy can utilize the primary tumor as an antigen reservoir to induce sustained antitumor immunity,and its combination with targeted agents or local therapies may yield synergistic effects.Early studies have demonstrated acceptable safety and preliminary efficacy;however,optimal patient selection,ideal combination strategies,and reliable predictive biomarkers remain to be established.High-quality randomized controlled trials are warranted to verify its impact on long-term survival and to optimize treatment approaches.
